Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
API
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.5%
USFDA APPLICATION NUMBER - 19219
DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.25% **...DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.25% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19814
Related Excipient Companies
Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Coating Systems & Additives
Parenteral
Controlled & Modified Release
Solubilizers
Topical
Disintegrants & Superdisintegrants
API Stability Enhancers
Fillers, Diluents & Binders
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Levobunolol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Levobunolol, including repackagers and relabelers. The FDA regulates Levobunolol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Levobunolol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Levobunolol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Levobunolol supplier is an individual or a company that provides Levobunolol active pharmaceutical ingredient (API) or Levobunolol finished formulations upon request. The Levobunolol suppliers may include Levobunolol API manufacturers, exporters, distributors and traders.
click here to find a list of Levobunolol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Levobunolol DMF (Drug Master File) is a document detailing the whole manufacturing process of Levobunolol active pharmaceutical ingredient (API) in detail. Different forms of Levobunolol DMFs exist exist since differing nations have different regulations, such as Levobunolol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Levobunolol DMF submitted to regulatory agencies in the US is known as a USDMF. Levobunolol USDMF includes data on Levobunolol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Levobunolol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Levobunolol suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Levobunolol Drug Master File in Japan (Levobunolol JDMF) empowers Levobunolol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Levobunolol JDMF during the approval evaluation for pharmaceutical products. At the time of Levobunolol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Levobunolol suppliers with JDMF on PharmaCompass.
A Levobunolol written confirmation (Levobunolol WC) is an official document issued by a regulatory agency to a Levobunolol manufacturer, verifying that the manufacturing facility of a Levobunolol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Levobunolol APIs or Levobunolol finished pharmaceutical products to another nation, regulatory agencies frequently require a Levobunolol WC (written confirmation) as part of the regulatory process.
click here to find a list of Levobunolol suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Levobunolol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Levobunolol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Levobunolol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Levobunolol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Levobunolol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Levobunolol suppliers with NDC on PharmaCompass.
Levobunolol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Levobunolol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Levobunolol GMP manufacturer or Levobunolol GMP API supplier for your needs.
A Levobunolol CoA (Certificate of Analysis) is a formal document that attests to Levobunolol's compliance with Levobunolol specifications and serves as a tool for batch-level quality control.
Levobunolol CoA mostly includes findings from lab analyses of a specific batch. For each Levobunolol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Levobunolol may be tested according to a variety of international standards, such as European Pharmacopoeia (Levobunolol EP), Levobunolol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Levobunolol USP).
LOOKING FOR A SUPPLIER?
